Literature DB >> 2580887

Morphology and antigenicity studies on reassortant influenza (H3N2) viruses for use in inactivated vaccines.

R M Pemberton, R Jennings, T L Smith.   

Abstract

Three influenza A (H3N2) reassortant whole virus vaccine strains with differing antibody-inducing capacities in hamsters were investigated morphologically and antigenically. Although initial measurements of virion circumference, from electron micrographs of vaccine preparations, suggested a relationship of small virion size with low immunogenicity, subsequent immunization with, and morphological investigation of, vaccine virions separated on sucrose gradients, failed to obtain populations whose antibody-inducing capacity clearly correlated with constituent virion density, size, morphology or integrity. However, antigenic investigation using single radial haemolysis (SRH) and monoclonal antibodies revealed significant differences in antigenic specificity between the strains. Furthermore, a series of H3N2 isolates, derived using standard reassortment procedures, also showed differences in antigenic specificity in their haemagglutination-inhibition (HI) reactions with monoclonal antibodies after five passages in allantois-on-shell cultures. Variation between these isolates and their A/Victoria parent virus could be detected using SRH and hamster sera raised against each isolate. These results demonstrate variation between candidate influenza A virus vaccine strains, all possessing the same surface (H3N2) glycoproteins, expressed as a consequence of the reassortant system used for their production.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580887      PMCID: PMC2129414          DOI: 10.1017/s002217240006143x

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  24 in total

1.  The response to inactivated influenza A (H3N2) vaccines: the development and effect of antibodies to the surface antigens.

Authors:  A F Smith; J R Davies
Journal:  J Hyg (Lond)       Date:  1977-06

2.  A low-speed centrifugation technique for the preparation of grids for direct virus examination by electron microscopy.

Authors:  H K Narang; A A Codd
Journal:  J Clin Pathol       Date:  1979-03       Impact factor: 3.411

3.  Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine.

Authors:  E D Kilbourne; J L Schulman; G C Schild; G Schloer; J Swanson; D Bucher
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

4.  Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutination proteins.

Authors:  W G Laver; R G Webster
Journal:  Virology       Date:  1968-02       Impact factor: 3.616

5.  Replication of influenza virus at elevated temperatures: production of virus-like particles with reduced matrix protein content.

Authors:  A P Kendal; J C Galphin; E L Palmer
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

6.  Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule.

Authors:  J W Yewdell; R G Webster; W U Gerhard
Journal:  Nature       Date:  1979-05-17       Impact factor: 49.962

7.  A single radial haemolysis technique for the measurement of influenza antibody.

Authors:  S M Russell; D McCahon; A S Beare
Journal:  J Gen Virol       Date:  1975-04       Impact factor: 3.891

8.  The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection.

Authors:  J S Oxford; G C Schild; C W Potter; R Jennings
Journal:  J Hyg (Lond)       Date:  1979-02

9.  Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines.

Authors:  J M Wood; G C Schild; R W Newman; V Seagroatt
Journal:  Dev Biol Stand       Date:  1977 Jun 1-3

10.  Antigenic variants of influenza A virus obtained in vitro.

Authors:  L R Haaheim; G C Schild
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.